vs
Side-by-side financial comparison of Foghorn Therapeutics Inc. (FHTX) and cbdMD, Inc. (YCBD). Click either name above to swap in a different company.
Foghorn Therapeutics Inc. is the larger business by last-quarter revenue ($9.2M vs $5.0M, roughly 1.8× cbdMD, Inc.). cbdMD, Inc. runs the higher net margin — -5.6% vs -234.3%, a 228.6% gap on every dollar of revenue. On growth, Foghorn Therapeutics Inc. posted the faster year-over-year revenue change (223.8% vs -1.9%). Over the past eight quarters, Foghorn Therapeutics Inc.'s revenue compounded faster (35.3% CAGR vs 7.1%).
Foghorn Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing novel therapies targeting the chromatin regulatory system to treat various types of cancer and other severe diseases. It advances a diverse pipeline of targeted drug candidates, conducting internal R&D and strategic partnerships to serve global patient populations.
cbdMD, Inc. is a U.S.-based consumer wellness company that manufactures and distributes hemp-derived CBD products, including tinctures, topicals, gummies, pet care items, and bath products. All offerings undergo third-party quality testing, and are sold via e-commerce platforms, brick-and-mortar retail stores, and wellness partner channels primarily across the United States.
FHTX vs YCBD — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $9.2M | $5.0M |
| Net Profit | $-21.7M | $-283.1K |
| Gross Margin | — | 59.8% |
| Operating Margin | -258.2% | -5.7% |
| Net Margin | -234.3% | -5.6% |
| Revenue YoY | 223.8% | -1.9% |
| Net Profit YoY | -11.1% | -1975.7% |
| EPS (diluted) | $-0.35 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $9.2M | $5.0M | ||
| Q3 25 | $8.2M | $4.7M | ||
| Q2 25 | $7.6M | $4.6M | ||
| Q1 25 | $6.0M | $4.7M | ||
| Q4 24 | $2.9M | $5.1M | ||
| Q3 24 | $7.8M | $4.6M | ||
| Q2 24 | $6.9M | $5.2M | ||
| Q1 24 | $5.0M | $4.4M |
| Q4 25 | $-21.7M | $-283.1K | ||
| Q3 25 | $-15.8M | $-680.0K | ||
| Q2 25 | $-17.9M | $-895.3K | ||
| Q1 25 | $-18.8M | $-480.8K | ||
| Q4 24 | $-19.5M | $15.1K | ||
| Q3 24 | $-19.1M | $-152.8K | ||
| Q2 24 | $-23.0M | $459.7K | ||
| Q1 24 | $-25.0M | $-3.0M |
| Q4 25 | — | 59.8% | ||
| Q3 25 | — | 58.8% | ||
| Q2 25 | — | 61.5% | ||
| Q1 25 | — | 62.3% | ||
| Q4 24 | — | 66.5% | ||
| Q3 24 | — | 53.9% | ||
| Q2 24 | — | 65.8% | ||
| Q1 24 | — | 59.0% |
| Q4 25 | -258.2% | -5.7% | ||
| Q3 25 | -226.9% | -14.5% | ||
| Q2 25 | -279.2% | -19.6% | ||
| Q1 25 | -385.0% | -10.2% | ||
| Q4 24 | -840.5% | -1.7% | ||
| Q3 24 | -305.5% | -6.9% | ||
| Q2 24 | -386.6% | -7.4% | ||
| Q1 24 | -558.3% | -35.4% |
| Q4 25 | -234.3% | -5.6% | ||
| Q3 25 | -194.4% | -14.4% | ||
| Q2 25 | -237.3% | -19.4% | ||
| Q1 25 | -316.4% | -10.1% | ||
| Q4 24 | -682.9% | 0.3% | ||
| Q3 24 | -244.9% | -3.4% | ||
| Q2 24 | -333.6% | 8.9% | ||
| Q1 24 | -495.4% | -68.8% |
| Q4 25 | $-0.35 | — | ||
| Q3 25 | $-0.25 | — | ||
| Q2 25 | $-0.28 | — | ||
| Q1 25 | $-0.30 | — | ||
| Q4 24 | $-0.23 | — | ||
| Q3 24 | $-0.31 | — | ||
| Q2 24 | $-0.45 | $-0.15 | ||
| Q1 24 | $-0.59 | $-1.35 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $80.9M | $3.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-108.5M | $9.0M |
| Total Assets | $198.1M | $11.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $80.9M | $3.4M | ||
| Q3 25 | $89.3M | $2.3M | ||
| Q2 25 | $72.6M | $1.1M | ||
| Q1 25 | $61.0M | $1.8M | ||
| Q4 24 | $55.5M | $2.0M | ||
| Q3 24 | $57.7M | $2.5M | ||
| Q2 24 | $138.9M | $2.4M | ||
| Q1 24 | $79.3M | $2.1M |
| Q4 25 | $-108.5M | $9.0M | ||
| Q3 25 | $-89.7M | $7.2M | ||
| Q2 25 | $-76.7M | $6.1M | ||
| Q1 25 | $-61.7M | $665.8K | ||
| Q4 24 | $-45.5M | $1.8M | ||
| Q3 24 | $-28.3M | $2.0M | ||
| Q2 24 | $-14.3M | $3.0M | ||
| Q1 24 | $-97.5M | $3.1M |
| Q4 25 | $198.1M | $11.8M | ||
| Q3 25 | $205.0M | $10.4M | ||
| Q2 25 | $226.2M | $9.9M | ||
| Q1 25 | $258.7M | $10.9M | ||
| Q4 24 | $284.0M | $11.5M | ||
| Q3 24 | $308.4M | $10.6M | ||
| Q2 24 | $328.6M | $13.8M | ||
| Q1 24 | $255.0M | $14.6M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-22.3M | $-812.5K |
| Free Cash FlowOCF − Capex | — | $-977.3K |
| FCF MarginFCF / Revenue | — | -19.5% |
| Capex IntensityCapex / Revenue | 0.0% | 3.3% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-2.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-22.3M | $-812.5K | ||
| Q3 25 | $-18.9M | $-240.7K | ||
| Q2 25 | $-21.0M | $-704.2K | ||
| Q1 25 | $-24.0M | $-189.5K | ||
| Q4 24 | $-24.5M | $-317.9K | ||
| Q3 24 | $-21.0M | $167.4K | ||
| Q2 24 | $-25.5M | $289.8K | ||
| Q1 24 | $-29.3M | $-704.1K |
| Q4 25 | — | $-977.3K | ||
| Q3 25 | — | $-243.6K | ||
| Q2 25 | $-21.0M | $-705.7K | ||
| Q1 25 | $-24.0M | $-205.0K | ||
| Q4 24 | $-25.0M | $-482.3K | ||
| Q3 24 | $-21.3M | $157.4K | ||
| Q2 24 | $-25.6M | — | ||
| Q1 24 | $-29.4M | $-708.7K |
| Q4 25 | — | -19.5% | ||
| Q3 25 | — | -5.2% | ||
| Q2 25 | -278.2% | -15.3% | ||
| Q1 25 | -403.2% | -4.3% | ||
| Q4 24 | -875.3% | -9.4% | ||
| Q3 24 | -273.0% | 3.5% | ||
| Q2 24 | -371.0% | — | ||
| Q1 24 | -583.1% | -16.2% |
| Q4 25 | 0.0% | 3.3% | ||
| Q3 25 | 0.0% | 0.1% | ||
| Q2 25 | 0.3% | 0.0% | ||
| Q1 25 | 0.5% | 0.3% | ||
| Q4 24 | 16.8% | 3.2% | ||
| Q3 24 | 4.0% | 0.2% | ||
| Q2 24 | 0.2% | 0.0% | ||
| Q1 24 | 2.0% | 0.1% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -21.06× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.63× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FHTX
Segment breakdown not available.
YCBD
| Sales Channel Directly To Consumer | $3.6M | 72% |
| Sales Channel Through Intermediary | $1.4M | 28% |
